The FDA has approved a new freeze-dried formulation of Jynneos (smallpox and mpox vaccine, live, non-replicating).

The global outbreak of mpox in 2022–23 affected more than 100 countries and grabbed the attention of the scientific community. Research on mpox has intensified since.

An advisory panel on vaccines meets, carefully, in the shadow of a health secretary who has often criticized it.